fleroxacin has been researched along with Cystic Fibrosis in 5 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 7.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 7.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 3.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 3.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| " Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered." | 2.40 | Drug disposition in cystic fibrosis. ( Pons, G; Rey, E; Tréluyer, JM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Y | 1 |
| Kim, TH | 1 |
| Tao, X | 1 |
| Kinzig, M | 1 |
| Landersdorfer, CB | 1 |
| Drescher, SK | 1 |
| Sutaria, DS | 1 |
| Moya, B | 1 |
| Holzgrabe, U | 1 |
| Sörgel, F | 2 |
| Bulitta, JB | 1 |
| Kearns, GL | 1 |
| Rey, E | 1 |
| Tréluyer, JM | 1 |
| Pons, G | 1 |
| Mimeault, J | 1 |
| Vallée, F | 1 |
| Seelmann, R | 1 |
| Ruel, M | 1 |
| LeBel, M | 1 |
| Akaniro, JC | 1 |
| Vidaurre, CE | 1 |
| Stutman, HR | 1 |
| Marks, MI | 1 |
2 reviews available for fleroxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Topics: Bile; Biotransformation; Child; Child, Preschool; Cystic Fibrosis; Fleroxacin; Humans; Liver; Liver | 1993 |
Drug disposition in cystic fibrosis.
Topics: Absorption; Anti-Infective Agents; Ciprofloxacin; Cloxacillin; Cyclosporine; Cystic Fibrosis; Flerox | 1998 |
3 other studies available for fleroxacin and Cystic Fibrosis
| Article | Year |
|---|---|
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Biotransformation; Body Composition; | 2018 |
Altered disposition of fleroxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug | 1990 |
Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Fleroxacin; | 1990 |